[Benefits and risks of current pharmacotherapy in the treatment of type 2 diabetes].

Abstract

The development of new drugs for the treatment of type 2 diabetes (T2DM) and metabolic disorders is currently one of the most innovative areas of drug development. However, a considerable number of newly developed drugs have either not reached the market and were stopped late in development or have been withdrawn after initial approval soon after market authorization due to serious safety concerns. How can drug safety problems be anticipated and, even more important, how can adverse events definitely caused by a drug be differentiated from incidences of naturally occurring diseases? This review article will provide an update about the state of the art treatment of type 2 diabetes and reflect on the newest available study evidence on glitazones, incretin mimetics (GLP-1 agonists and DPP-4 inhibitors), SGLT-2 inhibitors (gliflocines) and pan-PPAR agonists (glitazars). Furthermore, new and still experimental approaches for the treatment of T2DM, such as bardoxolone, salsalate and anakinra will be briefly reviewed.

• Authors: C Schindler, A Barthel, S Fischer, S R Bornstein, W Kirch
• Journal: Der Internist (Internist (Berl)) Vol. 53 Issue 4 Pg. 478, 480-5, 487 (Apr 2012) ISSN: 1432-1289 [Electronic] Germany
• Vernacular Title: Nutzen und Risiken der modernen Pharmakotherapie des Typ-2-Diabetes.
• PMID: 22388922 (Publication Type: English Abstract, Journal Article)

Chemical References

• Hypoglycemic Agents

Topics

• Diabetes Mellitus, Type 2 (drug therapy)
• Humans
• Hypoglycemic Agents (administration & dosage, adverse effects)
• Risk Assessment
• Risk Factors